Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease’s Statin Therapy in Men
Table 1
Values (median and IQR) of measured serum parameters for each experimental group at study entry and after 3 months.
Examined parameter
Experimental groups
Controls
ATV
ATV + vitEC
At study entry
AST (U/l)
23.7 (16.4–28.7)
42.7 (28.7–48.2) ()
41.5 (32.5–53.5) ()
ALT (U/l)
20.2 (14.5–28.4)
41.9 (29.8–69.7) ()
49.7 (39.1–67.8) ()
CRP (mg/l)
0.8 (0.3–1.6)
6.2 (5.6–8.3) ()
6.9 (5.1–9.8) ()
TG (mmol/l)
1.2 (0.9–1.5)
3.2 (1.3–6.3) ()
3.4 (1.6–5.5) ()
TC (mmol/l)
4.6 (3.0–5.7)
7.6 (6.6–8.7) ()
6.5 (5.9–7.3) ()
LDL-C (mmol/l)
2.4 (1.6–3.2)
6.0 (4.5–6.9) ()
5.1 (4.3–5.9) ()
HDL-C (mmol/l)
1.5 (1.0–1.9)
0.7 (0.3–1.4) ()
0.6 (0.3–0.9) ()
After 3 months
AST (U/l)
17.4 (15.0–24.1)
24.2 (20.1–25.3) ()
23.1 (18.7–33.7) ()
ALT (U/l)
23.8 (20.3–29.7)
30.8 (22.5–36.8) ()
31.2 (26.7–35.3) ()
CRP (mg/l)
1.1 (0.8–1.5)
3.2 (2.9–3.8) ()
3.1 (2.2–3.6) ()
TG (mmol/l)
1.8 (0.9–2.2)
1.3 (1.0–2.1) ()
1.2 (1.0–1.7) ()
TC (mmol/l)
4.8 (4.7–4.9)
4.8 (3.9–5.2) ()
5.7 (3.8–6.9)
LDL-C (mmol/l)
3.5 (2.2–3.9)
3.2 (2.9–3.4) ()
3.2 (3.1–3.3) ()
HDL-C (mmol/l)
1.2 (0.5–1.7)
1.5 (0.7–1.7)
1.6 (1.1–1.8) (p=0.015†)
Comparing marked group versus control at the same time point; comparing marked group versus same group at the study entry; only cases where are marked.
